GenSight Biologics SA 2016 IR
The report highlights GenSight Biologics' progress in developing novel gene therapies for neurodegenerative retinal diseases in 2016. Key milestones included completing patient enrollment for the Phase III REVERSE trial of GS010 and receiving orphan drug designation for GS030 in the European Union. Financially, the company successfully completed its initial public offering on Euronext Paris, raising approximately €45.2 million. GenSight also advanced its preclinical programs, initiating GLP toxicity studies for GS030 in non-human primates.
Company: GenSight Biologics SA
Sector: Professional & technical services
Country: France
Year: 2016
Type: IR
Pages: 264
Back to company
GenSight Biologics SA
Registration Document
The report highlights GenSight Biologics' progress in developing novel gene therapies for neurodegenerative retinal diseases in 2016. Key milestones included completing patient enrollment for the Phase III REVERSE trial of GS010 and receiving orphan drug designation for GS030 in the European Union. Financially, the company successfully completed its initial public offering on Euronext Paris, raising approximately €45.2 million. GenSight also advanced its preclinical programs, initiating GLP toxicity studies for GS030 in non-human primates.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Published
Apr 28, 2017
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management
Workplace Fatalities
Employees